Academy of Romanian Scientists *Volume 14, No. 1, 2025, pp. 215-225*
Annals Series on Biological Sciences Online ISSN 2285 – 4177

ORIGINAL PAPERS

OCULAR ALBINISM: AN INTEGRATED PERSPECTIVE ON CLINICAL MANIFESTATIONS, PATIENT IMPACT, AND LITERATURE INSIGHTS

Bianca-Mariana TIRZIMAN[1], Ioana VATA[2],
Alin CIOBICA[1,2,3,4], Ioannis MAVROUDIS[5,6]

[1]Faculty of Biology, Alexandru Ioan Cuza University of Iasi, Bd. Carol I no. 20A, 700505 Iasi, Romania
[2]Ioan Haulica" Institute, Apollonia University, Pacurari Street 11, 700511 Iasi, Romania
[3]Academy of Romanian Scientists
[4]"Olga Necrasov" Institute, Dept. of Biomedical Research, Romanian Academy, Bd. Carol I, no. 8, 700506 Iasi, Romania
[5]Department of Neuroscience, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
[6]Third Department of Neurology, Aristotle University of Thessaloniki, Greece
*Corresponding author email: ioanamacovei@yahoo.com

Abstract. *This paper explores ocular albinism, a rare genetic disorder caused by mutations in genes responsible for melanin production, primarily affecting the visual system. It describes the different types of ocular albinism, focusing on clinical features such as photophobia, nystagmus, and reduced visual acuity. Two real-life cases are presented to illustrate the condition's impact on patients' lives and the importance of accurate diagnosis. A comparison is also made between the manifestations of ocular albinism in humans and animal models, highlighting biological and genetic differences. Diagnostic methods include genetic testing, clinical evaluation, and ophthalmic imaging. Patient management emphasizes personalized treatments, visual aids, and psychosocial support. Early diagnosis and multidisciplinary interventions are essential for improving the quality of life of individuals with ocular albinism.*

Keywords: ocular albinism, genetic mutations, diagnosis, management, clinical cases, personalized approaches

DOI 10.56082/annalsarscibio.2025.1.215

Introduction

Albinism is a recessive genetic condition caused by mutations affecting melanocyte function, resulting in reduced or absent melanin synthesis, and consequently, low pigmentation of the skin, hair, and eyes. In isolated communities in Sub-Saharan Africa, where albinism prevalence is significantly higher than the global average (1 in 1000), lack of skin pigmentation leads to a higher risk of dermatological conditions, including skin cancer due to direct UV exposure. (Esther S Hong, 2006) Beyond medical issues, individuals in these regions often face discrimination and physical violence fuelled by cultural myths and superstitions. These challenges highlight the need for effective human rights protection and the promotion of social inclusion. (OHCHR, 2021)

In contrast, in Europe, North America, and Asia, albinism prevalence is much lower, and access to diagnosis and care is significantly more advanced. (OHCHR, 2021)

Types of albinism

While the most common type of albinism is oculocutaneous albinism (OCA), which affects both visual and skin structures, there are less obvious clinical forms, such as ocular albinism (OA). This type is characterized by the absence of skin signs and distinct genetic diagnostic features, often leading to underdiagnosis. Since some cases lack visible symptoms, OA can be mistaken for other congenital visual disorders like retinal dystrophies or optic atrophies. Accurate diagnosis requires a correlation between ophthalmologic examination, family history, and molecular genetic testing. (M T Bassi 1, 1995) (Charlotte C. Kruijt, 2000).

Ocular albinism is caused by mutations in the GPR143 gene located on the X chromosome. It follows an X-linked inheritance pattern, affecting mainly males, while females are usually healthy carriers (M T Bassi 1, 1995).

Historical context of ocular albinism

Long before modern medicine, ocular and oculocutaneous albinism were observed and described empirically, often misunderstood and associated with mysticism. References from ancient communities in Africa and Asia describe individuals with depigmented skin, hair, and eyes. Due to the lack of scientific understanding, such individuals were often subjected to myths and misinterpretation. Globally, the incidence of all forms of albinism varies, and it is estimated that about 1 in 70 people carry OCA-related genes. In Europe, during the medieval and 18th centuries, isolated cases were documented without detailed classification. (Karen Gronskov, 2007)

The hallmark signs of OA, such as reduced visual acuity, refractive errors, congenital nystagmus, photophobia, and foveal hypoplasia, were recognized in the 19th century as ophthalmology developed as a medical specialty. These anomalies significantly impact daily functioning and educational development, affecting depth perception, hand-eye coordination, and overall visual efficiency.

Recent studies, including "*Ophthalmological Manifestations of Oculocutaneous and Ocular Albinism: Current Perspectives*" (Magella M Neveu

1, 2022) also identified anormal development of the optic chiasm. This condition disrupts binocular vision and visual processing due to an anormal crossover of nerve fibers to the opposite cerebral hemisphere. Visual Evoked Potentials (VEPs) are used to detect this irregularity, showing interhemispheric differences when stimulating each eye—an indicator of misrouted optic fibers in albinism.

Thus, disrupted optic chiasm decussation is a major diagnostic criterion for ocular albinism, with crucial implications for patient evaluation and management. (Magella M Neveu 1, 2022)

With the adoption of Mendelian genetics in medical research in the latter half of the 20th century, albinism was confirmed to be an inherited disorder with recessive transmission. It was also demonstrated that multiple types of albinism exist, including X-linked ocular forms, predominantly affecting males. (BIN SHEN, 2001)

Genetic Considerations

Ocular albinism is a genetic condition caused by mutations that affect genes responsible for the production of melanin, the pigment essential for the coloration of the skin, hair, and eyes. Melanin plays a vital role in protecting the eyes from harmful ultraviolet radiation (UV) and is crucial for the normal development of vision. The most common mutations in ocular albinism involve the GPR143, OCA2, and TYR genes. These genes are involved in melanin synthesis and distribution in the body, and their dysfunction leads to insufficient eye pigmentation and significant visual impairment. (Karen Gronskov, 2007) (M T Bassi 1, 1995) (BIN SHEN, 2001)

Genetic Mutations Involved in Ocular Albinism

•**GPR143 gene** – This gene plays a central role in the development of classic ocular albinism (OA1), an X-linked form most commonly found in males. Since males have only one X chromosome (XY), a mutation on that chromosome leads to the condition. Females (XX) are typically carriers and do not show symptoms unless both X chromosomes carry the mutation, which is rare. GPR143 encodes a G-protein coupled receptor involved in melanin transport and synthesis in melanocytes. Mutations disrupt this function, causing reduced or absent eye pigmentation and visual issues such as nystagmus (involuntary eye movement), photophobia (light sensitivity), and poor visual acuity. These mutations can be detected through DNA sequencing. (Xiying Mao, 2021) (Bassi, 1995)

• **OCA2 gene** – Located on chromosome 15, this gene is typically linked to oculocutaneous albinism but may also cause forms of albinism affecting primarily the eyes, especially in milder cases. It encodes the P protein, involved in ion transport and pH regulation within melanosomes. Mutations in OCA2 can reduce melanin production, causing variable hypopigmentation and ocular symptoms such as nystagmus, photophobia, and low visual acuity. A 2024 study identified a new pathogenic variant in a Chinese family, expanding the known genetic spectrum and highlighting phenotypic variability. (David J. Green, 2024). (Yanan Wang, 2024)

•**TYR gene** – This gene encodes tyrosinase, a critical enzyme in the first steps of melanin biosynthesis. It converts the amino acid tyrosine into melanin. Mutations impair enzyme function and lead to decreased pigment in the eyes and sometimes the skin and hair. Patients with TYR mutations may experience severe forms of albinism, characterized by near-total depigmentation and pronounced visual deficits. (Balu Kamaraj, 2014)

Comparison of Genetic Mutations in Humans and Animal Models (Mus musculus and Danio rerio)

Table 1. Comparison of Genetic Mutations in Humans and Animal Models (Mus musculus and Danio rerio)-Original

FEATURE	HUMANS (HOMO SAPIENS)	ANIMAL MODELS (MUS MUSCULUS, DANIO RERIO)
Gene involved	GPR143 on X chromosome	GPR143 in mice; GPR143 homologs in zebrafish
Types of mutations	– **Point mutations** (a single base change in the DNA code) – **Deletions** (one or more bases missing)– **Insertions** (addition of one or more bases)	**Knock-out mutations** (intentional complete deactivation of a gene) – **Point mutations**
Clinical manifestations	Congenital nystagmus, retinal hypopigmentation, foveal hypoplasia, reduced visual acuity	In GPR143 knock-out mice, anomalies in melanosomes and visual deficiencies are observed. In zebrafish, mutations in the GPR143 homologs affect pigmentation development and retinal development
Research use	Genetic and clinical studies to understand OA and develop therapies	Animal models used to study the function of GPR143 and for gene therapy testing

Ocular albinism is primarily caused by mutations in the GPR143 gene, which is essential for the development and function of melanosomes in the pigment cells of the eye. The associated dysfunctions severely affect retinal development and visual acuity. Animal models, especially mice (Mus musculus) and zebrafish (Danio rerio), have played a crucial role in understanding the molecular mechanisms of the disease, providing a valuable platform for testing gene and pharmacological therapies. Advances in genomic editing and the discovery of new pharmacological compounds offer promising perspectives for the treatment of this condition. (Simona Torriano, 2021)

A study published in *Molecular Therapy* investigated GPR143 knockout mouse models (Mus musculus). These mice exhibit retinal anomalies similar to those observed in patients with OA1, including a reduced number of large melanosomes in the retinal pigment epithelium. Additionally, abnormal retinal development is observed, similar to the anomalies seen in patients with ocular albinism. These studies have been fundamental in elucidating the role of the GPR143 gene in ocular albinism, with research revealing how mutations in this gene affect eye development and melanosome formation, providing a foundation for the development of potential therapies (Auricchio, 2005)

A study published in *Neurogenetics* by Sabine L. Renninger and her collaborators (2011) shows that zebrafish (Danio rerio) are an efficient experimental model for investigating ocular albinism. By inducing mutations in the human GPR143 gene homolog, which is responsible for melanosome formation in the retinal pigment epithelium, the researchers observed significant disturbances in ocular pigmentation and retinal organization. These results highlight the functional conservation of the GPR143 gene across species and reinforce the use of zebrafish as a preclinical platform for studying the molecular mechanisms of OA1 and testing potential therapies. (Renninger, 2011)

Case Study: Comparative Analysis of European Cases of Ocular Albinism (OA1)

Introduction

Ocular Albinism type 1 (OA1) is a rare hereditary form of albinism caused by mutations in the GPR143 gene located on the X chromosome. The disease primarily affects males and is characterized by retinal hypopigmentation, foveal hypoplasia, and nystagmus. In recent years, documented cases from Europe have highlighted significant phenotypic variability, even within the same family, and have shed light on the clinical role of carrier females. (Lucia Micale, 2009) (M.J. Montoya Delgado∗, 2019)

Case Study – Spain

A study conducted on a Spanish family showed that even women who are carriers of a GPR143 mutation can exhibit subtle ophthalmological signs, such as changes in retinal pigmentation, supporting the need for thorough investigations in apparently asymptomatic carriers. (M.J. Montoya Delgado∗, 2019)

Source: *Archivos de la Sociedad Española de Oftalmología* (M.J. Montoya Delgado∗, 2019)

Patients: Mother and son

- **Genetic Diagnosis**: Mutation in GPR143
- **Clinical Manifestations in the san**:
  - Retinal hypopigmentation
  - Bilateral foveal hypoplasia (severe grade, evaluated by OCT)
  - Absence of macular autofluorescence
- **Manifestations in the mother (carrier)**:
  - Subtle changes in macular pigmentation
  - Hiperpigmented spots in the peripheral retina
  - Cavities in the retinal layers at the foveal level

Clinical Relevance: The study demonstrated that heterozygous women can present detectable ophthalmological signs, contradicting the idea that they are completely asymptomatic. Evaluating carriers becomes essential for diagnosis and genetic counselling.

Case Study – Italy

Two families from Italy, carrying the same genetic mutation, demonstrated the variability in clinical expression of ocular albinism, suggesting that genotype expression may be influenced by additional factors. (Lucia Micale, 2009)

Source: *Genetic Testing and Molecular Biomarkers* (Lucia Micale, 2009)

- **Patients**: Members from two Italian families
- **Genetic Diagnosis**: Mutation in the GPR143 gene in both families
- **Clinical Manifestations**:
  - Congenital nystagmus (not present in all patients)
  - Retinal hypopigmentation
  - Foveal hypoplasia of varying degrees

Key Observation: Although the mutation was identical in both families, the phenotypic expression varied significantly among individuals, showing a high degree of diversity in how the disease manifests.

Clinical Relevance: The study emphasizes the phenotypic variability of OA1 and the importance of correlating clinical findings with genetic testing. This has significant implications for diagnosis and family counseling.

Table 2. Comparative Analysis Table- original

FEATURE	CASE SPANIA	CASE ITALIA
GENE INVOLVED	GPR143	GPR143
INHERITANCE TYPE	X-linked recessive	X-linked recessive
CLINICAL PRESENTATION	on: full OA1; Mother: subtle signs	Family members with variable expression of the same mutation
NYSTAGMUS	Only son	Present in some patients, absent in others
KEY RELEVANCE	Carriers may show detectable changes	Disease expression varies between individuals

Diagnosis and Therapeutic Approach in Ocular Albinism

The diagnosis of ocular albinism (OA) is based on a combination of clinical criteria, advanced ophthalmologic investigations, and genetic testing. Due to the phenotypic variability in how the disease manifests in different individuals, a comprehensive assessment is essential, especially in cases with subtle or atypical features.

Clinical Evaluation – includes family history, physical examination, and visual function assessment. Common symptoms include:

- Congenital nystagmus (involuntary eye movements)
- Photophobia (increased light sensitivity)
- Reduced visual acuity
- Retinal hypopigmentation
- Iris transillumination (visible via slit-lamp biomicroscopy)

These manifestations vary significantly depending on the degree of involvement and may be absent in heterozygous (female) carriers. (Mervyn G Thomas, 2023)

Retinal Imaging – includes several techniques commonly used to study retinal structure:

- **Optical Coherence Tomography (OCT)** – a standard method for identifying foveal hypoplasia, a characteristic feature of ocular albinism. This technique allows detailed visualization of the retina and highlights the absence of normal foveal layering. Studies have shown that OCT can detect specific structural abnormalities in ocular albinism. (Patti S. Harvey CRA, 2006)
- **Retinal Autofluorescence (AF)** – useful for identifying the absence of macular pigment, a hallmark of ocular albinism. This method is especially valuable in moderate phenotypes or in female carriers, who may present with subtle signs. Studies have highlighted specific AF imaging changes in ocular albinism carriers. (Khan, 2018)

Electrophysiology

- **Visual Evoked Potentials (VEP)** – VEP is a neurophysiological test that measures the brain's electrical responses to visual stimuli.

In ocular albinism, the optic nerve fibres may undergo abnormal decussation, leading to an atypical pattern of cortical activation. Studies have demonstrated that VEP can detect these abnormalities in ocular albinism. (Dorey, 2003)

Genetic Testing

Genetic testing is essential for confirming a diagnosis of ocular albinism. Identifying mutations in the implicated genes—especially *GPR143* in type I ocular albinism—allows for:

- Accurate classification of the albinism type
- Appropriate family counselling
- Identification of asymptomatic carriers

Currently, there is no curative treatment for ocular albinism, but a personalized therapeutic approach can significantly improve patients' quality of life. Correction of refractive errors using glasses or contact lenses, along with the use of UV-filtering or photochromic lenses, is recommended to reduce photophobia. Low-vision optical devices, such as electronic magnifiers or telescopic systems, help maximize visual function. (optometrist, 2023)

Regarding nystagmus, oculomotor exercises and visual therapy can provide functional benefits. In severe cases, surgical interventions like the Kestenbaum-Anderson procedure may be considered, although outcomes vary. (Janice C. Law, 2025)

Early educational interventions tailored to a child's visual needs, along with psychological support for the patient and family, are essential for social and academic integration. Teachers are encouraged to understand the visual particularities of children with albinism. (NOAH, 2022)

Genetic counselling also plays a crucial role in X-linked conditions such as OA1, to inform families about recurrence risks and reproductive options. Female carriers of *GPR143* mutations may show subtle clinical signs and should undergo ophthalmological evaluation. (Karen Gronskov, 2007)

Multidisciplinary Management Protocol for Patients with Ocular Albinism

Table 3. Multidisciplinary Management Protocol for Patients with Ocular Albinism- original



Conclusions

Exploring ocular albinism highlights the complexity of an apparently rare condition, but one with significant implications in the realms of diagnosis, genetics, and psychosocial aspects. More than just a visual disorder, ocular albinism represents a convergence of genetics, ophthalmology, neuroscience, and human rights. The future lies in transdisciplinary approaches, where advanced genetic technologies, experimental models, and inclusive public policies can transform vulnerability into a model of best practices in personalized medicine.

Additionally, early diagnosis of ocular albinism is crucial not only for the proper management of the condition but also for preventing further complications that may affect both visual health and the social and educational integration of the patient. A correct and timely diagnosis enables specific interventions that can help improve the quality of life by addressing the patient's visual needs. For instance, early identification of associated issues, such as photophobia or nystagmus, allows for the implementation of personalized solutions, such as UV-filtering glasses or technologies to correct involuntary eye movements. This way, patients can benefit from clearer vision and reduce the risk of further eye damage due to intense light exposure.

Beyond the medical aspect, early diagnosis plays a crucial role in the psychosocial integration of the patient. The earlier the condition is detected, the sooner educational and social support measures can be adopted, thus preventing marginalization or psychological difficulties associated with stigmatization. Educational systems can provide tailored support, and families can better understand the special needs of their children, ensuring an environment conducive to their development. Furthermore, early intervention can help educate both the patient and those around them about the specifics of ocular albinism, thus aiding in the fight against prejudice and fostering social integration.

R E F E R E N C E S

[1] Auricchio, E. M. (2005). Amelioration of both Functional and Morphological Abnormalities in the Retina of a Mouse Model of Ocular Albinism Following AAV-Mediated Gene Transfer. *Molecular Therapy*.

[2] Balu Kamaraj, R. P. (2014). Mutational Analysis of Oculocutaneous Albinism: A Compact Review. *BioMed Research International*, 1-10.

[3] Bassi, M. T. (1995). The gene for ocular albinism type 1 (GPR143) is located on the X chromosome. *Nature Genetics*, 310-314.

[4] BIN SHEN, P. S. (2001). Ocular Albinism Type 1: More Than Meets The Eye. *Ophthalmic Genet.*, 241-248.

[5] Charlotte C. Kruijt, M. G. (2000). The Phenotypic Spectrum of Albinism. *British Journal of Ophthalmology*, 733–736.

[6] David J. Green, V. M. (2024). The co-occurrence of genetic variants in the TYR and OCA2 genes confers susceptibility to albinism. *Nature Communications*.

[7] Dorey, S. E. (2003). The clinical features of albinism and their correlation with visual evoked potentials. *British Journal of Ophthalmology*, 767–772.

[8] Esther S Hong, H. Z. (2006). Albinism in Africa as a public health issue. *BMC Public Health*, 6:212.

[9] Janice C. Law, M. P. (2025). Kestenbaum-Anderson Procedure. *american academy of ophtalmology* .

[10] Karen Gronskov, J. E.-N. (2007). Oculocutaneous albinism. *Orphanet Journal Of Rare Diseases*, 43.

[11] Khan, K. N. (2018). Detailed Retinal Imaging in Carriers of Ocular Albinism. *Retina*, 620–628.

[12] Lucia Micale, B. A. (2009). GPR143 mutational analysis in two Italian families with X-linked ocular albinism. *Genetic Testing and Molecular Biomarkers* , 473-477.

[13] M T Bassi 1, M. V. (1995). Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. *Nature Genetics*, 13-19.

[14] M.J. Montoya Delgado∗, M. A. (2019). *ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA*.

[15] Magella M Neveu 1, 2. S. (2022). Ophthalmological Manifestations of Oculocutaneous and Ocular Albinism: Current Perspectives. *PubMed*, 1569-1587.

[16] Mervyn G Thomas, M. P. (2023). Oculocutaneous Albinism and Ocular Albinism Overview. *GeneReviews*.

[17] NOAH. (2022). Information Bulletin – Assisting Students With Albinism. *National organization for albinism and hypopigmentation*.

[18] OHCHR. (2021). PEOPLE WITH ALBINISM. *United Nations Human Rights*, 1-140.

optometrist. (2023). Albinism and Low Vision.

[19] Patti S. Harvey CRA, R. A. (2006). Spectrum of Foveal Development in Albinism Detected with Optical Coherence Tomography. *Journal of American Association for Pediatric Ophthalmology and Strabismus*, 237-242.

[20] Renninger, S. L. (2011). Investigating the genetics of visual processing, function. *Neurogenetics*, 97-116.

[21] Simona Torriano, E. B. (2021). CRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in Induced Pluripotent Stem Cells from an Ocular Albinism Patient. *CRISPR Journal*.

[22] Xiying Mao, M. C. (2021). Identification of a novel GPR143 mutation in a large Chinese family with isolated foveal hypoplasia. *BMC Ophthalmology*, 156.

[23] Yanan Wang, Y. C. (2024). Genetic analysis of albinism caused by compound heterozygous mutations of the OCA2 gene in a Chinese family. *Hereditas*.